What is it about?
Flurbiprofen is a non-selective cyclo-oxygenase inhibitor, member of series of alkanoic acid derivatives, has anti-inflammatory, analgesic activity. Also used to treat gout, osteoarthritis, rheumatoid arthritis and is effective in inhibiting surgically induced miosis in human eyes while cataract extraction. Oral sustained release formulation as a novel matrix system of flurbiprofen tablets were prepared using Carboxy methylcellulose as release retardant.
Featured Image
Photo by Marcelo Leal on Unsplash
Why is it important?
The aim of present study was comparative bioavailability assessment of newly developed flurbiprofen matrix tablets for sustained delivery, with commercially available Froben SR.
Perspectives
The matrix tablets could also provide, sustained, gastrointestinal environmentalindependent release that may result in an improved therapeutic efficacy.
Dr. Muhammad Rizwan
Shanghai University
Read the Original
This page is a summary of: Comparative Bioavailability Assessment of Newly Developed Flurbiprofen Matrix Tablets and Froben SR® Tablets in Healthy Pakistani Volunteers, Journal of Bioequivalence & Bioavailability, January 2010, OMICS Publishing Group,
DOI: 10.4172/jbb.1000047.
You can read the full text:
Resources
Contributors
The following have contributed to this page
